Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cann GroupASX:CAN EV-to-EBITDA is 0.70 as of Jul. 15, 2026. The stock has 7 warning signs investors should review. Among 740 Drug Manufacturers companies, Cann Group ranks better than 97.3% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cann Group's enterprise value is A$20.65 Mil.
Cann Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$29.49 Mil. Therefore, Cann Group's EV-to-EBITDA for today is 0.70.
The historical rank and industry rank for Cann Group's EV-to-EBITDA or its related term are showing as below:
ASX:CAN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -79.11 Med: -5.72 Max: 0.73
Current: 0.7
During the past 9 years, the highest EV-to-EBITDA of Cann Group was 0.73. The lowest was -79.11. And the median was -5.72.
ASX:CAN's EV-to-EBITDA is ranked better than 97.3% of 740
companies
in the Drug Manufacturers industry
Industry Median: 13.025
vs ASX:CAN: 0.70
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Cann Group (ASX:CAN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cann Group's share price for today is A$0.004.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cann Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.012.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cann Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cann Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cann Group EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cann Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cann Group's EV-to-EBITDA falls into.
Cann Group's current Enterprise Value is A$20.65 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cann Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$29.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cann Group (ASX:CAN) has a EV-to-EBITDA of 0.70 as of Jul. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cann Group. According to the industry distribution chart, Cann Group ranks #20 out of 740 companies in the Drug Manufacturers industry, placing it in the top 2.7%.
Is Cann Group's EV-to-EBITDA too high?
Cann Group's current EV-to-EBITDA is 0.70. The Drug Manufacturers industry median EV-to-EBITDA is 13.03. Cann Group's value of 0.70 is 94.6% below this industry median. Based on the distribution chart, Cann Group ranks #20 out of 740 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Cann Group's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cann Group ranks #20 out of 740 companies for EV-to-EBITDA. This places Cann Group in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.03. Cann Group's value of 0.70 is 94.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.03, based on 740 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cann Group's current EV-to-EBITDA of 0.70 is 94.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cann Group. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cann Group's current EV-to-EBITDA is 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cann Group stock overvalued right now?
Based on GuruFocus' analysis, Cann Group (ASX:CAN) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 80% below its estimated fair value. The current EV-to-EBITDA is 0.70 and 94.6% below the Drug Manufacturers industry median of 13.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cann Group (ASX:CAN), the current EV-to-EBITDA is 0.70 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes under the licenses and permits issued to the company, the development and manufacture (via third-party arrangements) of finished product formulations. Geographically, the company operates in Europe and Australia. The company derives maximum revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CAN has been successfully added to your 
